Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp once daily plus mealtime insulin aspart versus insulin detemir plus mealtime insulin aspart in children and adolescents with type 1 diabetes
2012-003566-41Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec, insulin aspart and insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c. Started Jun 2013; status: completed.
02
Drugs
insulin degludecinsulin aspartinsulin detemir
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2012-003566-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003566-41.